SPO Global (SPO Global) Total Receivables : $0.46 Mil (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is SPO Global Total Receivables?

SPO Global's Total Receivables for the quarter that ended in Sep. 2023 was $0.46 Mil.

SPO Global Total Receivables Historical Data

The historical data trend for SPO Global's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SPO Global Total Receivables Chart

SPO Global Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Receivables

Get a 7-Day Free Trial

0.05

0.01

0.04

SPO Global Quarterly Data
	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep22	Sep23
Total Receivables	Get a 7-Day Free Trial															0.04	0.09	0.06	-	0.46

SPO Global Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

SPO Global Total Receivables Related Terms

Thank you for viewing the detailed overview of SPO Global's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

SPO Global (SPO Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Conglomerates » SPO Global Inc (OTCPK:SPOM) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jinan Pharma Valley, 27th Floor Block A J, Shandong, CHN, 33634

Website

http://www.gerpanghealthcare.com

SPO Global Inc is a holding company whose strategic plan is to acquire interests in emerging young businesses and provide financing, advice and guidance to assist them in realizing their potential. The Company is implementing an acquisition roll-up model of acquiring sales, marketing, and manufacturing businesses. The business scope of the company includes bio-pharmaceutical Research and development, development and sales of medical informatization software, medical high-tech introduction, production and sales of medical quality supplies, dietary supplements, and medicine, as well as agents and sales of medical equipment supplies.

Executives

Jeffrey Louis Feuer	officer: Chief Financial Officer	21860 BURBANK BLVD SUITE 380, WOODLAND HILLS CA 91367
Richard H Ryan	officer: Chief Operating Officer	21860 BURBANK BLVD., NORTH BUILDING SUITE 380, WOODLAND HILLS CA 91367
Michael Braunold	director, officer: Chief Executive Officer	C/O AUBIENT CORP, 1033 BECON ST, BROOKLINE MA 02446
Sidney Braun	director	SUITE 404, 6711 MISSISSAUGA ROAD, MISSISSAUGA A6 L5N 2W3
Pauline Dorfman	director	183 REINER ROAD, TORONTO A6 M3H 2L8
Israel Sarussi	10 percent owner, officer: Chief Technology Officer	C/O SPO, SUITE 380, 21860 BURBANK BLVD., WOODLAND HILLS CA 91367